Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CCEL with free AI briefings, catalyst countdowns, and dilution alerts.

CCEL · CRYO CELL INTERNATIONAL INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4.2M Cash on Hand
CF+ Cash Runway
Follow CCEL by email Get an email when CCEL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CCEL, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Cord Tissue Mesenchymal Stromal Cells Autism Phase 2 · NCT04089579 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CCEL holds $4.2M in cash and short-term investments (as of Aug 31, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CCEL files for a raise →

👥 Who Owns CCEL

Insiders 33.5% Other 5%+ holders 6.8% Institutions (14 holders) 13.1% Public and other holders 46.6%
HolderTypeShares% of sharesAs of
David Portnoy
Chairman, Co-CEO, Director, 10% owner · +679,879 options
Insider 1,515,637 18.80% 2026-08-05
Mark L. Portnoy
Co-CEO, Director, 10% owner · +267,222 options
Insider 935,768 11.61% 2026-01-07
Camac Partners, LLC 5%+ holder (13D) 551,081 6.83% 2026-07-02
Oleg Mikulinsky
Chief Information Officer · +103,777 options
Insider 104,349 1.29% 2026-01-07
Harold D. Berger
Director · +55,200 options
Insider 57,901 0.72% 2026-10-27
Jill M Taymans
VP Finance, CFO · +74,000 options
Insider 52,896 0.66% 2026-05-28
Daniel Mizrahi
Director · +37,100 options
Insider 30,634 0.38% 2026-10-27

Share count 8,062,650 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CCEL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CCEL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.